China, Nov. 16 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Exploratory Study of Immunotherapy Combined with Dual-Pathway Targeted Inhibition Strategy in First-Line HER2-Overexpressing and PD-L1 Positive Advanced Non-Small Cell Lung Cancer'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600136714
Registration Time: 2026/11/14
Type: Interventional study
Primary Sponsor: The Fifth Medical Center of the Chinese People's Liberation Army General Hospital
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=350366
Published by HT Digital Content Services with permission from Health Daily Digest....